Briggi Daniel R, Reilly James, Garcia Josiel, Kupperman Wyatt
H. Ben Taub Department of Physical Medicine and Rehabilitation, Baylor College of Medicine, One Baylor Plaza, Houston, TX, 77030, USA.
Johns Hopkins University, Baltimore, MD, USA.
Curr Pain Headache Rep. 2025 Apr 21;29(1):75. doi: 10.1007/s11916-025-01388-x.
The provision of a review of current literature on the cost-effectiveness of employing SCS in the treatment of CRPS.
Four studies were included in this review, with authorship in the United States, Canada, Europe, and Australia. Each study individually supported the cost-effectiveness of SCS in the treatment of CRPS, with the incremental cost of one quality-adjusted life year found to be AUD 2,321 - USD 22,084, all below a willingness to pay estimated at USD 50,000. One of the four studies was rated American Academy of Neurology (AAN) Grade II, three of the four studies were rated AAN Grade III, and an overall Class C evaluation was assigned to this evidence. SCS can be cost-effective in the treatment of patients with CRPS when considering a time horizon of at least ten years. Current evidence, however, remains weak and less invasive options remain first-line.
对目前关于采用脊髓刺激（SCS）治疗复杂性区域疼痛综合征（CRPS）的成本效益的文献进行综述。
本综述纳入了四项研究，作者分别来自美国、加拿大、欧洲和澳大利亚。每项研究均单独支持SCS治疗CRPS的成本效益，发现每增加一个质量调整生命年的增量成本为2321澳元至22084美元，均低于估计的50000美元的支付意愿。四项研究中有一项被评为美国神经病学学会（AAN）II级，四项研究中有三项被评为AAN III级，该证据整体被评为C级。当考虑至少十年的时间范围时，SCS治疗CRPS患者可能具有成本效益。然而，目前的证据仍然薄弱，侵入性较小的选择仍然是一线治疗方法。
